Testing a medicine to reduce inflammation in pneumonia patients
Part of Infections, Lungs & breathing clinical trials.
This trial tests if a medicine called icosapent ethyl can reduce inflammation in blood vessels for adults hospitalized with pneumonia. It aims to see if this treatment can help prevent complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are hospitalized with pneumonia confirmed by chest imaging and symptoms like fever, cough, or mucus.
- You are 18 years or older.
- You do not have an active inflammatory condition such as rheumatoid arthritis, Crohn's disease, or lupus.
- You have not had cancer (except certain skin cancers or early cervical cancer) in the past 3 years.
- You are not pregnant, breastfeeding, or planning to become pregnant without using two forms of birth control.
- You are not allergic to icosapent ethyl, fish, or shellfish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called icosapent ethyl (a purified fish oil) can help reduce plaque buildup in heart arteries and lower inflammation in people with heart disease. Researchers will use imaging and blood tests to see if it protects your heart.
This trial tests a new medicine (OPT101) for people hospitalized with pneumonia and sepsis—where a lung infection causes body-wide inflammation and low oxygen. It aims to help patients who need extra oxygen but are not yet on a breathing machine.
This trial compares different antibiotic strategies for children with pneumonia who are being treated as outpatients. The goal is to find the best approach to treat the infection and help your child recover.
This study tests a medication called icosapent ethyl (a type of fish oil) to see if it can reduce inflammation in dangerous heart plaques. It might help prevent heart attacks or strokes in people with certain high-risk plaque features.
This trial tests a new drug called SR1375 for adults with severe community-acquired pneumonia (a lung infection) who are not improving with standard antibiotics. It may help reduce inflammation and speed up recovery.
This Phase 3 trial tests whether an anti-clot “blood thinner” can reduce complications from community-acquired pneumonia in hospitalized adults who need extra oxygen. It may help by lowering harmful clot-related effects during serious lung infection.
Hear when a new Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.